Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor i...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Bahlis, Nizar J., Sutherland, Heather, White, Darrell, Sebag, Michael, Lentzsch, Suzanne, Kotb, Rami, Venner, Christopher P., Gasparetto, Cristina, Del Col, Aldo, Neri, Paola, Reece, Donna, Kauffman, Michael, Shacham, Sharon, Unger, T. J., Jeha, Jacqueline, Saint-Martin, Jean-Richard, Shah, Jatin, Chen, Christine
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2018
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6302280/
https://ncbi.nlm.nih.gov/pubmed/30352784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-06-858852
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍